Immunotherapy in Advanced SCAC: Translating Emerging Evidence into Community Practice - CME - Guideline Central

CME

Title
Immunotherapy in Advanced SCAC: Translating Emerging Evidence into Community Practice
Link
Description
This program will prepare clinicians with a comprehensive understanding of the appropriate management of patients with advanced SCAC and the clinical utility of agents that could significantly impact patient outcomes. Clinicians will be informed about the most recent developments in advanced SCAC management, including the use of IO-based therapies for the treatment of advanced SCAC. The program will provide education on the most recent safety and efficacy data and guideline recommendations on how to use IO agents appropriately, helping clinicians feel more comfortable implementing these therapies into their practice and ultimately improving patient outcomes.
Target Audience
This program is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with anal carcinoma.
Learning Objectives
  • Apply current clinical evidence and emerging data on immune checkpoint inhibitors to inform treatment decisions for patients with advanced SCAC.
  • Identify patients with advanced SCAC who may benefit from immunotherapy based on clinical characteristics and treatment history.
  • Integrate immunotherapy into comprehensive treatment plans for patients with advanced SCAC with attention to immune-related adverse event management and collaborative treatment discussions.
Estimated Duration
60 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Oncology
Disclosures and Disclaimers
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, PleXus Communications and/or Incyte. Authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Accredited Providers
  • PleXus Communications
  • Medical Education Resources
Commercial Support
  • Incyte Corporation
Activity Expiration Date
April 15, 2027
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit1 CreditsACCME- Accreditation Council for Continuing Medical Education
Nursing1 Contact HoursANCC - American Nurses Credentialing Center
Pharmacy1 Contact HoursACPE- Accreditation Council for Pharmacy Education
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.